L-Linalool
Based on 1 Customer Validation
L-Linalool ((-)-Linalool) is a naturally derived monoterpene alcohol with oral activity, possessing neuroprotective, anti-inflammatory, and antioxidant activities. L-Linalool is a 5-HT3 receptor inhibitor and a benzodiazepine-responsive GABAA receptor enhancer. L-Linalool reduces nitrite and lipid peroxidation in the brain and partially prevents the decrease of striatal dopamine, DOPAC, and HVA. L-Linalool exhibits neuroprotective effects in hemiparkinsonian rats, cortical oxygen-glucose deprivation injury, and Alzheimer's disease models. L-Linalool prevents the decrease in tyrosine hydroxylase and dopamine transporter expression. L-Linalool can be used in research related to diseases such as Parkinson's disease and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 126-91-0
- Formula: C10H18O
- Molecular Weight:154.25
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All 5-HT Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
5-HT3 Receptor |
In Vitro
L-Linalool is a natural acyclic monoterpene alcohol that exists as two enantiomers, 3R-(-)-Linalool and 3S-(+)-Linalool[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 250-280 g)[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; once daily; 15 days
-
Result:Attenuated apomorphine‑induced rotational behaviour in 6‑OHDA‑lesioned rats across 25‑100 mg/kg doses.
Reversed 6‑OHDA‑triggered behavioural deficits in open‑field and forced‑swimming assays, restoring readouts close to sham‑operated controls.
Alleviated striatal dopamine‑metabolite depletion in lesioned striatum at 25‑100 mg/kg.
Suppressed oxidative‑stress‑related nitrite and lipoperoxidation elevation in striatum and hippocampus.
Preserved TH and DAT immunoreactivity in lesioned striatum, with 50 mg/kg bringing DAT near‑sham levels.
Chemical Information
-
CAS No. 126-91-0
-
Appearance Liquid (Density: 0.858 g/cm3)
-
Molecular Weight 154.25
-
Formula C10H18O
-
Color Colorless to light yellow
-
SMILES
C=C[C@@](C)(CC/C=C(C)/C)O
-
Synonyms
(-)-Linalool
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : 200 mg/mL (1296.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (32.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (32.41 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. de Lucena JD, et al. L-linalool exerts a neuroprotective action on hemiparkinsonian rats. Naunyn-Schmiedeberg's archives of pharmacology. 2020 Jun;393(6):1077-1088. [Content Brief]
[2]. An Q, et al. Recent updates on bioactive properties of linalool. Food & function. 2021 Nov 01;12(21):10370-10389. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.4830 mL | 32.4149 mL | 64.8298 mL | 162.0746 mL |
| 5 mM | 1.2966 mL | 6.4830 mL | 12.9660 mL | 32.4149 mL | |
| 10 mM | 0.6483 mL | 3.2415 mL | 6.4830 mL | 16.2075 mL | |
| 15 mM | 0.4322 mL | 2.1610 mL | 4.3220 mL | 10.8050 mL | |
| 20 mM | 0.3241 mL | 1.6207 mL | 3.2415 mL | 8.1037 mL | |
| 25 mM | 0.2593 mL | 1.2966 mL | 2.5932 mL | 6.4830 mL | |
| 30 mM | 0.2161 mL | 1.0805 mL | 2.1610 mL | 5.4025 mL | |
| 40 mM | 0.1621 mL | 0.8104 mL | 1.6207 mL | 4.0519 mL | |
| 50 mM | 0.1297 mL | 0.6483 mL | 1.2966 mL | 3.2415 mL | |
| 60 mM | 0.1080 mL | 0.5402 mL | 1.0805 mL | 2.7012 mL | |
| 80 mM | 0.0810 mL | 0.4052 mL | 0.8104 mL | 2.0259 mL | |
| 100 mM | 0.0648 mL | 0.3241 mL | 0.6483 mL | 1.6207 mL |
L-Linalool Related Classifications
HY-116195 Related Classifications
Powered by Bioz